Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sevasemten · EDG-5506, EDG-005506

Small molecule · developed by Edgewise Therapeutics

Phase 2 Most advanced trial

EWTX Developer

6 Registered trials

What is Sevasemten?

Sevasemten is an oral small-molecule compound studied in Duchenne and Becker muscular dystrophies and other neuromuscular disorders.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: EDG-5506, EDG-005506, Radiolabeled EDG-5506 Intravenous, Radiolabeled EDG-5506 Suspension
Drug type: Small molecule
Therapy area: Musculoskeletal, Neurology
Developer: Edgewise Therapeutics, Inc. (EWTX)
Also in trials of: MEDP
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: JT5OYR0WUK

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06100887	Phase 2	Duchenne Muscular Dystrophy	Active not recruiting	EWTX
NCT06066580	Phase 2	Becker Muscular Dystrophy	Enrolling by invitation	EWTX
NCT05291091	Phase 2	Becker Muscular Dystrophy	Completed	EWTX
NCT05540860	Phase 2	Duchenne Muscular Dystrophy	Active not recruiting	EWTX
NCT05730842	Phase 1	Healthy Volunteer	Completed	EWTX
NCT05492734	Phase 1	Muscular Dystrophies	Completed	EWTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Duchenne Muscular DystrophyBecker Muscular DystrophyGenetic Diseases, InbornHealthy VolunteerMuscular DiseasesMuscular Disorders, AtrophicMuscular DystrophiesMusculoskeletal DiseasesNervous System DiseasesNeuromuscular Diseases

More from Edgewise Therapeutics

EDG-15400 Phase 2 EDG-7500 Phase 2

Sources

ClinicalTrials.gov NCT05291091

Updated Oct 3, 2026. Something wrong or missing? Report it on the EWTX page.

Follow EWTX, the company behind Sevasemten

See EWTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EWTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z